Prosperity Financial Group Inc. Sells 225 Shares of Zoetis Inc. (NYSE:ZTS)

Prosperity Financial Group Inc. trimmed its position in Zoetis Inc. (NYSE:ZTS) by 5.4% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 3,945 shares of the company’s stock after selling 225 shares during the period. Prosperity Financial Group Inc.’s holdings in Zoetis were worth $771,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ZTS. Darwin Wealth Management LLC bought a new position in Zoetis during the third quarter valued at about $31,000. First Personal Financial Services bought a new position in shares of Zoetis during the 3rd quarter valued at approximately $33,000. Capital Performance Advisors LLP purchased a new stake in shares of Zoetis during the 3rd quarter worth approximately $33,000. Quarry LP raised its holdings in shares of Zoetis by 273.2% in the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after purchasing an additional 153 shares during the period. Finally, LRI Investments LLC purchased a new position in Zoetis in the first quarter valued at approximately $43,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on ZTS shares. Stifel Nicolaus raised their target price on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, September 18th. BTIG Research upped their price objective on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. Piper Sandler lifted their target price on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Argus upgraded shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $221.44.

Zoetis Trading Up 0.1 %

Shares of ZTS stock opened at $176.96 on Monday. The company has a market capitalization of $79.84 billion, a PE ratio of 33.26, a price-to-earnings-growth ratio of 2.71 and a beta of 0.90. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92. The business’s fifty day moving average is $185.62 and its 200 day moving average is $180.72. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The firm had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.29 billion. During the same quarter last year, the firm posted $1.36 EPS. The company’s revenue was up 11.6% compared to the same quarter last year. On average, equities research analysts anticipate that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be given a dividend of $0.432 per share. The ex-dividend date is Thursday, October 31st. This represents a $1.73 annualized dividend and a yield of 0.98%. Zoetis’s payout ratio is presently 32.52%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.